Meir Medical Center
Kfar Saba, Israel
NCT Number: NCT00874068
The purpose of this study is to determine the effect of high sn-2 palmitic acid based infant formula on bone strength parameters.
Looking for future studies?
Notify MeUp to 1 month
All sexes
Interventional
Not applicable
Kfar Saba, Israel
InFatTM is an advanced basic-fat ingredient, which mimics the fat composition and properties of human milk fat and enabling optimal intake of the essential calcium and energy (in the form of fatty acids) and easy digestion. These benefits are the results of a unique fatty acid composition on the glycerol backbone, which ensure high level of palmitic acid at the middle (sn-2) position.
The purpose of this study is to determine the effect of high sn-2 palmitic acid based infant formula on bone strength parameters, anthropometric parameters, wellbeing and stool characteristics in term and preterm infants.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
high sn-2 palmitic acid oil based infant formula
Other names: high sn-2 palmitic acid, structured triglyceride
standard vegetable oil based infant formula
Other names: standard vegetable oil
Time frame: baseline, 40 corrected gestation weeks, 6 weeks, 12 weeks
Time frame: baseline, 40 corrected gestation weeks, 6 weeks, 12 weeks
Time frame: baseline, 40 corrected gestation weeks, 6 weeks, 12 weeks
Enzymotec
Industry
The Effects of Dietary Palmitic Acid Triacylglyceride Position on Anthropometric Measures, Bone Strength Parameters, Stool Characteristics and Stool Biochemistry in Preterm and Term Infants
Acronym: InFat_002
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02459327
Behavior, Behavioral Symptoms
New York, United States
View Trial DetailsNCT05284591
Behavior, Blood Protein Disorders
Frankfurt am Main, Hesse, Germany
View Trial DetailsNCT04757428
Behavior, Personal Satisfaction
Cairo, Egypt
View Trial DetailsNCT05953870
Behavior, Personal Satisfaction
Bellinzona, Switzerland
View Trial Details